Zinc Finger Protein-Based Prognostic Signature Predicts Survival in Lung Adenocarcinoma

  • 0Wuxi School of Medicine, Jiangnan University, Wuxi 214122, China.

|

|

Summary

This summary is machine-generated.

This study identifies 21 zinc finger proteins (ZNFs) as key predictors of survival in lung adenocarcinoma (LUAD). A developed risk score model using these ZNFs can distinguish between high-risk and low-risk patients, aiding in treatment strategies.

Area Of Science

  • Oncology
  • Genetics
  • Bioinformatics

Background

  • Zinc finger proteins (ZNFs) are critical regulators of gene expression implicated in cancer development.
  • Their specific roles in lung adenocarcinoma (LUAD) pathogenesis are not fully understood.
  • Understanding ZNF functions is crucial for identifying new therapeutic targets.

Purpose Of The Study

  • To investigate the prognostic significance of zinc finger proteins in lung adenocarcinoma.
  • To develop a predictive model for patient survival based on ZNF expression.
  • To identify potential molecular targets for LUAD treatment.

Main Methods

  • Utilized TCGA and GEO datasets for transcriptional data analysis.
  • Applied univariate Cox regression and LASSO algorithm for marker selection and risk score model development.
  • Validated findings through multivariable Cox regression and cell-based expression analysis (qRT-PCR).

Main Results

  • A risk score model incorporating 21 ZNFs was developed to predict clinical outcomes in LUAD.
  • Patients in the low-risk group exhibited significantly better survival rates than those in the high-risk group.
  • Transcriptional profiles of key ZNFs showed concordance between bioinformatics data and experimental cell models.

Conclusions

  • The developed prognostic framework utilizing ZNFs demonstrates significant biomarker potential for LUAD survival prediction.
  • This research offers novel insights into the molecular mechanisms of LUAD.
  • Identified ZNFs represent potential targets for developing innovative therapeutic strategies against lung adenocarcinoma.